

**Use of mechanistic modelling to assess inter-individual variability and inter-species differences in active uptake in human and rat hepatocytes**

Karelle Ménochet, Kathryn E. Kenworthy, J. Brian Houston and Aleksandra Galetin

Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, M13 9PT, United Kingdom (K.M., J.B.H. and A.G.)

Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Ware, United Kingdom (K.E.K.)

**Running title:** Modeling of hepatic uptake in human hepatocytes

Corresponding author: Dr A. Galetin  
School of Pharmacy and Pharmaceutical Sciences,  
University of Manchester, Stopford Building  
Oxford Road,  
Manchester, M13 9PT, UK  
Tel: (+) 44 161 275 6886  
Fax: (+) 44 161 275 8349  
Email: [Aleksandra.Galetin@manchester.ac.uk](mailto:Aleksandra.Galetin@manchester.ac.uk)

Text: 40 pages

Tables: 4

Figures: 8

Abstract: 251

Introduction: 771

Discussion: 1588

References: 53

Abbreviations: ABT, 1-aminobenzotriazole;  $CL_{\text{active,u}}$ , unbound active uptake clearance;  $CL_{\text{uptake,u}}$ , unbound total uptake clearance;  $CL_{\text{met}}$ , metabolic clearance; CYP, cytochrome P450; DDI, drug-drug interaction; DMSO, dimethylsulfoxide; DPBS, Dulbecco's phosphate buffer saline;  $f_{\text{u,cell}}$ , intracellular unbound fraction;  $f_{\text{u,med}}$ , unbound fraction in the media;  $K_{\text{m,u}}$ , unbound affinity constant;  $\text{Log}D_{7.4}$ , distribution coefficient between octanol and water at pH 7.4; M1, 2-despiperidyl-2-amino repaglinide; M2, 2-despiperidyl-2(5-carboxypentylamine) repaglinide; M4, 3'-hydroxy repaglinide; NCE, new chemical entity; OATP, organic anion transporting protein;  $P_{\text{diff,u}}$ , unbound passive diffusion clearance;  $V_{\text{max}}$ , maximum uptake rate.

## Abstract

Inter-individual variability in activity of uptake transporters is evident in vivo, yet limited data exist in vitro, confounding the in vitro-in vivo extrapolation. The uptake kinetics of seven OATP substrates was investigated over a concentration range in plated cryopreserved human hepatocytes. Active uptake clearance ( $CL_{active,u}$ ), bidirectional passive diffusion ( $P_{diff}$ ), intracellular binding and metabolism were estimated for bosentan, pitavastatin, pravastatin, repaglinide, rosuvastatin, telmisartan and valsartan in HU4122 donor using a mechanistic two-compartment model in Matlab. Full uptake kinetics of rosuvastatin and repaglinide were also characterized in two additional donors, whereas for the remaining drugs  $CL_{active,u}$  was estimated at a single concentration. The  $K_{m,u}$  and  $P_{diff}$  values were consistent across donors, whereas  $V_{max}$  was on average up to 2.8-fold greater in donor HU4122. Consistency in  $K_{m,u}$  allowed extrapolation of single concentration uptake activity data and assessment of inter-individual variability in  $CL_{active}$  across donors. The maximal contribution of active transport to total uptake differed between donors, for example 85-96% and 68-87% for rosuvastatin and repaglinide, respectively; however, in all the cases the active process was the major contributor. In vitro-in vivo extrapolation indicated a general under-prediction of hepatic intrinsic clearance; an average empirical scaling factor of 17.1 was estimated based on seven drugs investigated in three hepatocyte donors; donor-specific differences in empirical factors are discussed. Uptake  $K_{m,u}$  and  $CL_{active,u}$  were on average 4.3- and 7.1-fold lower in human hepatocytes compared to our previously published rat data. Strategy for the use of rat uptake data to facilitate the experimental design in human hepatocytes is discussed.

## Introduction

Over the past decade human hepatocytes have become the tool of choice to study metabolism of new chemical entities (NCE) due to the expression of phase I and II metabolizing enzymes alongside transporters (Hewitt et al., 2007; Soars et al., 2007; Hallifax et al., 2010; Ohtsuki et al., 2012). As the quality and characterization of the cells available have improved, investigation of hepatic disposition of new NCEs in donors expressing various levels of enzyme and transport is becoming more plausible (Parker and Houston, 2008; Chiba et al., 2009; Badolo et al., 2011; Ulvestad et al., 2011; Jones et al., 2012). However, inter-donor variability in transporter expression and activity has yet to be addressed; experience with metabolic clearances prediction (Hallifax and Houston, 2009) indicate that this may be problematic. Recently, reports have been published on characterization of active uptake in reasonably large sets of human hepatocyte donors using typical OATP probes (Badolo et al., 2011; De Bruyn et al., 2011). Badolo et al. (2011) reported variation of 53% in the uptake clearance of estradiol-17 $\beta$ -glucuronide when studied in six lots of cryopreserved human hepatocytes. De Bruyn et al (2011) observed a 30-fold range in estrone-3-sulfate uptake when measured in 14 human hepatocyte donors. However, to our knowledge, there has been no investigation to date of the uptake of a substantial set of drugs in the same human hepatocyte donors and following a standardized experimental approach.

In the present study uptake of seven OATP substrates was characterized over a range of concentration and time points in plated cryopreserved human hepatocytes (donor HU4122). Rosuvastatin, pravastatin, pitavastatin, telmisartan, valsartan, repaglinide and bosentan were selected, as these drugs have been reported to interact with at least one of the major OATPs expressed in the liver (OATP1B1 or OATP1B3), in either in vitro systems and/or in clinical studies involving patients with polymorphic variants of these transporters (Niemi et al., 2005; Ieiri et al., 2009; Watanabe et al., 2009; Yabe et al., 2011). These drugs have also been involved in clinical drug-drug interactions (DDI) due to inhibition of active transport, either in

isolation or in conjunction with a reduction in metabolism (Niemi et al., 2003; Simonson et al., 2004; Kajosaari et al., 2005). In addition, rosuvastatin, pravastatin and pitavastatin have been recommended by the International Transporter Consortium as probe substrates to assess the potential risk of DDIs involving OATPs of NCE in development (Giacomini et al., 2010). Therefore, a mechanistic characterization of their *in vitro* uptake kinetics is required. In this study, advantages and limitations associated with each of these substrates have been highlighted.

In the case of rosuvastatin and repaglinide, full kinetic profiles were assessed in three human hepatocyte donors. Rosuvastatin was selected as a representative of a drug undergoing minimal metabolism, while repaglinide allowed the simultaneous assessment of uptake and metabolism. For the remaining drugs, uptake was assessed at a single low concentration in two additional hepatocyte donors. In those cases, *a priori* information obtained from extensive rat hepatocyte studies (Ménochet et al., 2012) and detailed kinetic data from the donor HU4122 were applied in the mechanistic model to estimate uptake kinetic parameters and assess inter-individual variability in active uptake across hepatocyte donors.

Recently, we have proposed a mechanistic two-compartment model for simultaneous assessment of uptake, passive diffusion, intracellular binding and metabolism *in vitro* (Ménochet et al., 2012). Application of the mechanistic model developed to describe the interplay between multiple processes was previously assessed in rat hepatocytes and extended here to human hepatocytes; hence, the inter-species differences in uptake kinetics of seven OATP substrates were investigated. This is of particular relevance as the data generated in rat hepatocytes are valuable to improve our understanding of mechanisms driving the disposition of the compound using physiologically-based pharmacokinetic models and subsequent translation to human transporter-mediated pharmacokinetics (Poirier et al., 2009; Watanabe et al., 2009). While the similarities and differences in metabolizing enzymes between rat and human are acknowledged (Martignoni et al., 2006; Hagenbuch and Gui, 2008; Kotani et al.,

2011), a limited number of studies have elucidated the details of species differences in substrate specificities and activity of uptake transporters (Hagenbuch and Meier, 2004; Nakakariya et al., 2008).

The aim of the present study was to apply the mechanistic two-compartment model to estimate uptake kinetics of seven selected substrates in human hepatocytes. The use of single concentration experiments in conjunction with mechanistic model was explored for characterization of uptake kinetics of these substrates in three human hepatocyte donors; subsequently, the impact of inter-individual variability in the uptake activity on the prediction of hepatic clearance in vivo was investigated. Finally, comparison of uptake kinetic parameters obtained in rat and human hepatocytes was performed for the drugs selected.

## **Material and Methods**

**Chemicals.** Bosentan, pitavastatin, pravastatin, rosuvastatin, telmisartan and valsartan were obtained from Sequoia Research Products (Pangbourne, UK). Repaglinide, mibefradil, verapamil and indomethacin were purchased from Sigma-Aldrich (Poole, UK). Telmisartan acyl- $\beta$ -D-glucuronide, 2-despiperidyl-2-amino repaglinide (M1), 2-despiperidyl-2(5-carboxypentylamine) repaglinide (M2), 3'-hydroxy repaglinide (M4) and repaglinide acyl- $\beta$ -D-glucuronide were obtained from Toronto Research Chemicals (Toronto, Canada). All other reagents were purchased from Sigma-Aldrich (Poole, UK) and of the highest grade available.

**Preparation of the human hepatocytes.** The human biological samples were sourced ethically and their research use was in accord with the terms of the informed consents. Cryopreserved human hepatocytes from three donors (Lots HU4122, HU4199 and HU8089) were purchased from Invitrogen (Paisley, UK). The hepatocytes were removed from liquid nitrogen storage, immediately thawed at 37°C for 90 seconds and transferred in pre-warmed Cryopreserved Hepatocyte Recovery Medium (AP Sciences, Columbia, MD). Cells were centrifuged at 100 g for 10 min and resuspended in Cryopreserved Hepatocyte

Plating Medium (AP Sciences, Columbia, MD) at 4°C. Cells were counted under a microscope using a haemocytometer and the viability was assessed using the trypan blue exclusion method. Only cell suspensions with viability >80% were used. Cell suspension was diluted to a density of 750,000 (donor HU4122) or 800,000 cell/mL (donors HU4199 and HU8089). 0.5 mL of cell suspension was added to each well of 24-well, collagen I-coated plates (BD Biosciences, Oxford, UK). Cells were incubated for 6 hr at 37°C in an atmosphere containing 5% CO<sub>2</sub> to allow to adhere to the collagen. Incubations were carried out with cells from a single donor to avoid issues associated with differential plating efficiency between the three batches which could result in unknown proportion of cells from individual donor.

**Measurement of uptake in human hepatocytes.** Uptake studies were performed as described previously (Ménochet et al., 2012). Briefly, for all drugs of interest, uptake was measured over a range of seven concentrations comprised between 0.1 and 300 µM in donor HU4122 (0.1, 1, 10, 20, 30, 100 and 300 µM). The maximum concentration studied for telmisartan was 100 µM due to the limited solubility of this compound in aqueous buffer. The maximum concentration used for repaglinide was 100 µM as formation of the metabolites was linear only up to that concentration. These concentrations were chosen as uptake  $K_m$  ranging between 11.5 and 48.5 µM have been reported in human hepatocytes for pravastatin and telmisartan, respectively (Nakai et al., 2001; Ishiguro et al., 2006). No corresponding data were available for bosentan, pitavastatin and rosuvastatin in this cellular system. In addition, full uptake kinetics of rosuvastatin and repaglinide was measured in donors HU4199 and HU8089. In these donors, uptake of bosentan, pitavastatin, telmisartan and valsartan was measured at a single concentration of 1 µM. A single concentration of 10 µM was used for pravastatin due to limitations in the analytical method for this drug. Substrates were dissolved in dimethylsulfoxide (DMSO) and diluted in Dulbecco's Phosphate Buffer Saline (DPBS) (maximum 1% DMSO). Plating medium was removed. Cell monolayers were rinsed twice with pre-warmed DPBS and pre-incubated with fresh DPBS for at least 20 min. Incubations

were started by the addition of 400  $\mu\text{L}$  of substrate pre-warmed at 37°C. After incubation for 30, 60, 90 and 120 sec at 37°C, substrate was collected for analysis and the cell monolayer were rinsed three times with 800  $\mu\text{L}$  DPBS. 200  $\mu\text{L}$  of water was added in each well in order to lyse the cells. Substrate samples and cellular lysates were stored at -20°C until analysis. In order to inhibit phase I metabolism of repaglinide and bosentan, a CYP pan-inhibitor 1-aminobenzotriazole (ABT) was added at a concentration of 1 mM in the pre-incubation and incubation buffers used for these two drugs (Mico et al., 1988). ABT has been reported not to affect the activity of uptake transporters in transfected HEK293 cells (Plise et al., 2010). Due to lack of nonspecific UGT inhibitor, formation of repaglinide and telmisartan glucuronide was monitored during the uptake experiment. Pitavastatin glucuronidation was not monitored considering minor importance of this pathway (Fujino et al., 2003) and inclusion of metabolic clearance was expected to have a minimal impact on the uptake parameter estimates for this drug. In each experiment, uptake of 1  $\mu\text{M}$  rosuvastatin and 1  $\mu\text{M}$  estrone-3-sulfate was measured as a control of the uptake activity. Each time and concentration point was carried out in duplicate.

**Sample preparation and LC-MS/MS analysis.** Cell lysates and substrate samples were thawed and quenched with an equal volume of methanol containing 1  $\mu\text{M}$  internal standard. Samples were placed at -20°C for at least an hour before being centrifuged for 10 min at 6720 g. 20  $\mu\text{L}$  supernatant were analyzed by LC-MS/MS on either a Waters 2795 HPLC coupled with a Micromass Quattro Ultima mass spectrometer (Waters, Milford, MA) or a Waters 2695 HPLC coupled with a Micromass Quattro Micro mass spectrometer (Waters, Milford, MA). Analytes were separated through a Luna C18 column (3  $\mu\text{m}$ , 50 x 4.6 mm) (Phenomenex, Torrance, CA). The flow rate through the HPLC system was 1 mL/min and was split to 0.25 mL/min before entering the mass spectrometer. With the exception of estrone-3-sulfate, all analytes were ionized by positive electrospray. LC-MS/MS analysis of all the drugs studied performed as described previously (Ménochet et al., 2012). Telmisartan glucuronide, M1, M2,



M4 and repaglinide glucuronide cell concentrations were also monitored for modeling purposes.

**Determination of unbound fraction in the incubation media.** Nonspecific binding of the drugs to the cellular membrane and the experimental support was assessed by measuring the media concentrations over time at each incubation concentrations, as described previously (Ménochet et al., 2012). Media was assumed to be free of protein as the hepatocytes were attached to the support and the monolayers were rinsed thoroughly before the start of the incubation. Media concentrations at  $t_0$  were estimated by extrapolation of the linear regression of the media concentration vs. time plot at each incubation concentration. Unbound fraction in the media ( $f_{u,med}$ ) was subsequently expressed as the slope of the linear regression of the measured media concentrations at  $t_0$  vs. the initial incubation concentrations.

**Determination of uptake kinetic parameters using a mechanistic two-compartment modeling approach.** A mechanistic two-compartment model was previously developed by the authors to estimate the uptake kinetics of the same seven OATP substrates in plated rat hepatocytes (Ménochet et al., 2012). In that case, experiments carried out at 10 substrate concentrations over 45-90 min (8 time-points) were suitable to estimate with precision active uptake kinetics ( $K_{m,u}$  and  $V_{max}$ ), bidirectional passive diffusion clearance ( $P_{diff,u}$ ) and intracellular binding ( $f_{u,cell}$ ). Due to the cost of human hepatocytes, experiments in the present study were limited to 7 concentrations over 2 min (4 time-points), restricting the number of data points available for modeling in comparison to rat hepatocytes. In the initial analysis  $f_{u,cell}$  estimates obtained from the human hepatocyte data were associated with large standard error ( $CV > 100\%$ , data not shown), analogous to the trends seen in rat data when reduced time and concentration points were used (Ménochet et al., 2012). In order to maintain similar degrees of freedom and level of precision in the parameter estimates,  $f_{u,cell}$  obtained in the rat hepatocytes after incubations over 45-90 min were set as constant in the mechanistic two-compartment model used for the analysis of the human hepatocyte data;  $f_{u,cell}$  values used

are listed in Table 1. Use of extended incubation times in rat study resulted in CV<21% for the  $f_{u_{cell}}$  for all drugs studied with the exception of rosuvastatin.

The model, implemented in Matlab v7.10<sup>®</sup> (2010) (Mathworks, Natick, MA, USA), allows simultaneous fitting of all concentration and time points. In addition to the kinetics of the active uptake, this model describes the bidirectional passive diffusion of the drug through the cellular membrane and the intracellular binding. After isolation, hepatocytes lose their polarization and efflux transporters are internalized (Hewitt et al., 2007; Bow et al., 2008). Therefore, active efflux was assumed to be negligible, consistent with other studies focusing on estimation of uptake in isolated or short term cultured hepatocytes. Equations 1 and 2 describe the changes in cell and media concentrations over time, respectively.

$$\frac{dS_{cell}}{dt} = \frac{\frac{V_{max} \times S_{med,u}}{K_{m,u} + S_{med,u}} + P_{diff,u} \times S_{med,u} - P_{diff,u} \times S_{cell} \times fu_{cell}}{V_{cell}} \quad (1)$$

$$\frac{dS_{med,u}}{dt} = \frac{-\frac{V_{max} \times S_{med,u}}{K_{m,u} + S_{med,u}} - P_{diff,u} \times S_{med,u} + P_{diff,u} \times S_{cell} \times fu_{cell}}{V_{med}} \quad (2)$$

where  $S_{cell}$  and  $S_{med,u}$  are the intracellular and unbound media concentrations, respectively.  $K_{m,u}$ ,  $V_{max}$ ,  $P_{diff,u}$  and  $f_{u_{cell}}$  are the unbound affinity constant, the maximum uptake rate, the unbound passive diffusion clearance and the unbound intracellular fraction, respectively. An intracellular volume,  $V_{cell}$ , of  $3.9 \mu\text{L}/10^6$  cells is used in this study (Reinoso et al., 2001). Media volume,  $V_{med}$ , is  $400 \mu\text{L}$ .  $CL_{active,u}$  the unbound active uptake clearance, was expressed as the ratio of  $V_{max}$  over the  $K_{m,u}$ . The total unbound uptake clearance ( $CL_{uptake,u}$ ) included both the active component ( $CL_{active,u}$ ) and clearance via passive diffusion. The contribution of the active transport to the total uptake was expressed as the ratio of  $CL_{active,u}$  over  $CL_{uptake,u}$  and was calculated over the range of concentrations studied.

Initial media concentrations were obtained by correcting the nominal substrate concentrations by  $f_{u,med}$ . Initial cell concentrations were obtained from the linear regression of the first four time points for each of the concentration at time zero. The rationale was that not all the drug could be washed from the cell membranes or experimental plates with DPBS during the washing steps. However, due to the differences in volumes between the cell and media compartments, the largest amount of drug found in the cells at time 0 represented <1% of the total amount of compound present in the incubation. Cell concentrations were used as input data in the model. At least 48 data points were available to model the uptake kinetics of each drug. In the first instance, kinetic parameters were optimized with open boundaries for  $K_{m,u}$ ,  $V_{max}$  and  $P_{diff,u}$ . The greatest uncertainty was associated with the estimation of  $P_{diff,u}$ . To improve the precision of this estimate, a second round of optimization was performed using the results of the preliminary optimization as a priori information. For that purpose, the following boundaries were set:  $K_{m,u} \pm 20\%$ ,  $V_{max} \pm 50\%$ ,  $P_{diff,u} \pm 100\%$ .

**Simultaneous modeling of telmisartan uptake and metabolism.** In human, telmisartan is transformed to single glucuronide metabolites by UGT1A3 (Stangier et al., 2000; Yamada et al., 2011). Because no specific inhibitor of UGTs is available, modeling of telmisartan uptake and metabolism were performed simultaneously. Mechanistic two-compartment model was extended to account for the formation of telmisartan glucuronide over time, as illustrated in Figure 1. Equation 3 describes the changes in telmisartan cell concentrations during the uptake experiment, whereas changes in telmisartan glucuronide cell concentrations are defined by equation 4. Changes in media concentrations over time were defined as shown above in equation 2.

$$\frac{dS_{cell}}{dt} = \frac{\frac{V_{max} \times S_{med,u}}{K_{m,u} + S_{med,u}} + P_{diff,u} \times S_{med,u} - S_{cell} \times f_{u,cell} \times (P_{diff,u} + CL_{met,u})}{V_{cell}} \quad (3)$$

$$\frac{dS_{\text{met}}}{dt} = \frac{CL_{\text{met,u}} \times S_{\text{cell}} \times fu_{\text{cell}}}{V_{\text{cell}}} \quad (4)$$

where  $S_{\text{met}}$  and  $CL_{\text{met,u}}$  are telmisartan glucuronide cell concentrations and the unbound metabolic clearance, respectively.  $CL_{\text{met,u}}$  obtained previously from the metabolite formation assay in donor HU4122 was used as a constant in the model in addition to  $fu_{\text{cell}}$  in order to estimate accurately  $K_{\text{m,u}}$ ,  $V_{\text{max}}$  and  $P_{\text{diff,u}}$ , as telmisartan glucuronide was not monitored in this initial uptake assay. In donors HU4199 and HU8089, formation of telmisartan glucuronide was monitored in the uptake assay carried out at 1  $\mu\text{M}$ .

**Determination of uptake kinetic parameters and metabolic clearance of repaglinide using a mechanistic modeling approach.** In human, repaglinide is metabolized by CYP3A4 and CYP2C8 to five metabolites, including M1, M2 and M4. A glucuronide metabolite formed by UGT1A1 has also been reported recently (Bidstrup et al., 2003; Yamada et al., 2011; Sall et al., 2012). In the first instance, uptake of repaglinide was investigated in isolation, in the presence of ABT, in donor HU4122 and no metabolism was taken into account, as repaglinide glucuronide was not commercially available when the initial experiment was conducted. The mechanistic two-compartment model described by equations 1 and 2 was used to analyze the data. Subsequently, uptake and metabolism of repaglinide were studied simultaneously in donors HU4199 and HU8089. Incubations were carried out in absence of ABT and extended to 15 min (6 time-points). M1, M2, M4 and repaglinide glucuronide cell concentrations were monitored in addition to repaglinide and the linearity of the metabolite formation confirmed over the incubation period. Preliminary analysis indicated that  $CL_{\text{int}}$  for M1 was 16- and 28-fold lower than M2 and M4 in donor HU8089. Therefore, subsequent analysis focused on monitoring the formation of M2, M4 and repaglinide glucuronide in human hepatocytes during the uptake experiment (Supplemental Figure S1) and these metabolites were taken into account for modeling purposes. In a similar manner to telmisartan, cell sub-compartments were added to the mechanistic two-

compartment model to describe the formation of each metabolite over time (Figure 1). Equation 5 describes the changes in repaglinide cell concentrations over time, while equations 6 to 8 describe the formation of M2, M4 and repaglinide glucuronide, respectively. Changes in media concentrations are described by equation 2.

$$\frac{dS_{\text{cell}}}{dt} = \frac{\frac{V_{\text{max}} \times S_{\text{med,u}}}{K_{\text{m,u}} + S_{\text{med,u}}} + P_{\text{diff,u}} \times S_{\text{med,u}} - S_{\text{cell}} \times fu_{\text{cell}} \times (P_{\text{diff,u}} + CL_{\text{met,M2,u}} + CL_{\text{met,M4,u}} + CL_{\text{met,gluc,u}})}{V_{\text{cell}}} \quad (5)$$

$$\frac{dS_{\text{M2,cell}}}{dt} = \frac{V_{\text{max,M2}} \times S_{\text{cell}} \times fu_{\text{cell}}}{K_{\text{m,M2,u}} + S_{\text{cell}} \times fu_{\text{cell}}} \quad (6)$$

$$\frac{dS_{\text{M4,cell}}}{dt} = \frac{V_{\text{max,M4}} \times S_{\text{cell}} \times fu_{\text{cell}}}{K_{\text{m,M4,u}} + S_{\text{cell}} \times fu_{\text{cell}}} \quad (7)$$

$$\frac{dS_{\text{Gluc,cell}}}{dt} = \frac{CL_{\text{met,gluc,u}} \times S_{\text{cell}} \times fu_{\text{cell}}}{V_{\text{cell}}} \quad (8)$$

where  $S_{\text{M2,cell}}$ ,  $S_{\text{M4,cell}}$  and  $S_{\text{Gluc,cell}}$  are M2, M4 and repaglinide glucuronide cell concentrations, respectively.  $K_{\text{m,M2,u}}$ ,  $V_{\text{max,M2}}$ ,  $K_{\text{m,M4,u}}$ ,  $V_{\text{max,M4}}$  and  $CL_{\text{met,gluc,u}}$  are the kinetic parameters describing the formation of M2, M4 and repaglinide glucuronide, respectively. Cell and media initial concentrations were estimated as described previously (Ménochet et al., 2012). Initial metabolite cell concentrations were obtained from the linear regression of the first four time points. Initial metabolite cell concentrations were never greater than 0.1% of the total amount of drug present in the incubation. To optimize the amount of information obtained from each experiment and to describe the potential saturation of the formation of each metabolite, metabolic clearances were replaced by Michaelis-Menten kinetic parameters ( $K_{\text{m,u}}$  and  $V_{\text{max}}$ ) in equations 6 to 8. The impact of the use of the various modeling approaches and associated error on the uptake and metabolism kinetic parameter estimates was investigated.

**Inter-individual variability in uptake between three human hepatocyte donors.** To investigate variability in uptake activity between human hepatocyte donors, uptake of rosuvastatin and repaglinide was measured in three human hepatocyte donors over a range of concentrations, following mechanistic modeling data analysis, as described in sections above. For the remaining drugs in the dataset (pravastatin, valsartan, bosentan and pitavastatin) uptake was measured over 2 min in donors HU4199 and HU8089 using a single substrate concentration. Based on full kinetic characterization data obtained for rosuvastatin and repaglinide in three donors,  $K_{m,u}$  and  $P_{diff,u}$  values were assumed to be constant among donors (Tables 2 and 3). Mechanistic model defined in equation 1 was therefore used to fit the  $V_{max}$  using the data obtained over 2 min at a single substrate concentration, keeping  $K_{m,u}$ ,  $P_{diff,u}$  and  $f_{u,cell}$  constant (as obtained in donor HU4122). The fitting routine was performed in Matlab v. 7.10<sup>®</sup> (2010) using lsqnonlin function; the differential equations were solved using the ODE45 solver. An analogous method was applied for telmisartan, but in this case metabolic clearance was also taken into account in the fitting routine as shown in the equation 3. Subsequently,  $CL_{active,u}$  for the remaining five drugs could be calculated as  $V_{max}/K_{m,u}$  ratio. In order to verify the validity of the assumptions stated above,  $CL_{active,u}$  was calculated for each drug in donor HU4122 using the single concentration (1  $\mu$ M) method and compared with the  $CL_{active,u}$  values obtained from the full kinetic characterization.

**Statistical analysis.** A Jacobian approach was used in Matlab v7.10<sup>®</sup> (2010) to estimate standard error associated with each parameter estimate generated from the mechanistic two-compartment model (Landaw and DiStefano, 1984). Coefficients of variation (CV) were calculated and expressed as percentages to assess the quality of each parameter estimate. Goodness of fit was assessed by visual inspection of the data and minimum objective function value. Arithmetic means, standard errors and CVs associated with each kinetic parameter were calculated for each drug when results in the three human

hepatocyte donors were available. P-values were calculated using a Student's t-test. Results were deemed significant for  $p < 0.05$ .

**Collation of uptake measurements data of estrone-3-sulfate in human hepatocytes from commercial supplier.** Uptake rate values of estrone-3-sulfate in human cryopreserved hepatocytes were collated from the characterization spreadsheets available from BD Gentest (Oxford, UK) between September 2008 and September 2011 ([http://wwwbdbiosciences.com/nvCategory.jsp?action=SELECT&form=formTree\\_catBean&item=774729](http://wwwbdbiosciences.com/nvCategory.jsp?action=SELECT&form=formTree_catBean&item=774729)). Uptake was measured at 2  $\mu\text{M}$  over 3 min using 200,000 human hepatocytes in suspension per incubation. Using the provided uptake rates, uptake clearances were calculated from the ratio of the uptake rate over the substrate concentration to allow comparison with data obtained in the three human hepatocyte donors studied here. Demographic information (age, gender) for each donor available from BD Gentest was also collated and data were assessed for any trends. Collated data are summarized in the Supplementary Material, Table S1.

**Prediction of hepatic clearance in human.** Prediction of in vivo clearance was carried out using unbound intrinsic clearance ( $\text{CL}_{\text{int,u}}$ ) term (Shitara and Sugiyama, 2006), as described in equation 9:

$$\text{CL}_{\text{int,u}} = (\text{CL}_{\text{active,u}} + \text{P}_{\text{diff,u}}) \times \frac{\text{CL}_{\text{met,u}} + \text{CL}_{\text{bile,u}}}{\text{CL}_{\text{met,u}} + \text{CL}_{\text{bile,u}} + \text{P}_{\text{diff,u}}} \quad (9)$$

$\text{CL}_{\text{active,u}}$ ,  $\text{CL}_{\text{met,u}}$  and  $\text{P}_{\text{diff,u}}$  represent the total unbound uptake clearance, the unbound metabolic clearance and the passive diffusion clearance; all parameters were obtained experimentally and scaled up to a whole liver using physiological scaling factors and expressed in mL/min/kg. Hepatocellularity and liver weight values of  $120 \times 10^6$  cells/g liver and 21.4 g of liver per of kg body weight, respectively, were used (Brown et al., 2007).  $\text{CL}_{\text{bile,u}}$  is the unbound biliary clearance and was obtained by multiplying the fraction of the dose recovered unchanged in the feces after intravenous administration by the unbound total

plasma clearance. In the case of bosentan,  $CL_{met,u}$  was obtained from the literature (Lave et al., 1996). Details for the individual drugs are provided in Supplementary Material Table S2. Values obtained from in vitro results were compared to the in vivo intrinsic clearances estimated from the literature data and expressed as described in equation 10.

$$CL_{int,h} = \frac{CL_h}{fu_b \times \left(1 - \frac{CL_h}{Q_h}\right)} \quad (10)$$

where  $CL_h$  is the hepatic blood clearance after intravenous administration corrected for renal clearance and  $fu_b$  is the unbound fraction in the blood. No  $CL_h$  was available for pitavastatin; therefore, this drug was omitted from the comparison between predicted and observed hepatic clearances.

Preliminary in vitro-in vivo extrapolation has shown under-prediction of the intrinsic hepatic clearance. Therefore, empirical scaling factors required for  $CL_{active,u}$  were calculated for each drug in all three donors. In the first instance, a mean scaling factor per individual donor was used and the three individual empirical scaling factors were then applied to correct corresponding  $CL_{active,u}$  in that particular donor. In addition, the average empirical scaling factor obtained for all drugs in all three donors (16 data points in total) was calculated and applied to correct  $CL_{active,u}$ . The accuracy and bias associated with each predictive approach were compared by calculation of the root mean square error (rmse) and the geometric mean fold error (gmfe) (Gertz et al., 2010), as described in equations 11 and 12, respectively.

$$rmse = \sqrt{\frac{1}{N} \sum (\text{Predicted} - \text{Observed})^2} \quad (11)$$

$$gmfe = 10^{\frac{1}{N} \sum \left| \log \frac{\text{Predicted}}{\text{Observed}} \right|} \quad (12)$$



**Comparison of uptake data obtained in rat and human hepatocytes.** Uptake data obtained in three human hepatocyte donors were compared with the results generated previously in rat hepatocytes for the seven same drugs using a similar experimental and modeling approach (Ménochet et al., 2012);  $\text{LogD}_{7.4}$  data were also taken from previous publication. Fold difference in  $K_{m,u}$ ,  $\text{CL}_{\text{active},u}$  and  $\text{P}_{\text{diff},u}$  were calculated and inter-species differences were considered.

## Results

**Mechanistic modeling of uptake in donor HU4122.** Full uptake kinetics of seven drugs was investigated in human hepatocyte donor HU4122 using a mechanistic modeling approach defined previously.  $K_{m,u}$ ,  $V_{max}$  and  $P_{diff,u}$  were estimated from the data generated over 2 min incubations and are summarized in Table 1. Corresponding kinetic profiles and goodness of fit plots obtained with this model are shown in the Supplementary Material (Figures S2 and S3, respectively).  $K_{m,u}$  values ranged 14-fold, from 1.59 to 22.5  $\mu\text{M}$  for pitavastatin and bosentan, respectively. A greater difference in  $V_{max}$  between the drugs investigated resulted in a 34-fold range in  $CL_{active,u}$ . Pravastatin showed the lowest active uptake clearance (2.77  $\mu\text{L}/\text{min}/10^6$  cells) while telmisartan was the most readily taken up by the cell with  $CL_{active,u}$  of 95.2  $\mu\text{L}/\text{min}/10^6$  cells.  $P_{diff,u}$  was the kinetic parameter that differed the most between the seven drugs, with a range of 222-fold, from 0.064 to 14.1  $\mu\text{L}/\text{min}/10^6$  cells for valsartan and telmisartan, respectively.

All media concentrations were corrected for nonspecific binding to the experimental support;  $f_{u_{med}}$  was  $> 0.6$  for all drugs investigated in the current dataset. Nonspecific binding had a minimal influence on the uptake kinetics of all drugs of interest, and most specifically on rosuvastatin, repaglinide and pravastatin which showed  $f_{u_{med}}$  values  $>0.9$ . Using  $f_{u_{cell}}$  values derived from rat studies allowed modeling of human hepatocyte uptake data and accurate estimation of all kinetic parameters for the drugs in the current dataset (CV $<30\%$ ), with the exception of the  $K_{m,u}$  and  $V_{max}$  values for pravastatin (CV of 194 and 36%, respectively).  $f_{u_{cell}}$  values ranged from 0.024 to 1 for telmisartan and valsartan, respectively. Inter-experiment variability of rosuvastatin and estrone-3-sulfate uptake used as controls was 39% and 40%, respectively (n=8, donor HU4122).

Differing extents of active uptake and passive diffusion were observed amongst the seven drugs investigated, as shown in Figure 2. Only in the case of rosuvastatin, repaglinide and valsartan was the active process responsible for  $\geq 50\%$  of the total uptake over the full

range of concentrations investigated. However, at the lowest concentrations studied, the maximal proportion of total uptake due to active process was >90% for all the drugs investigated. Thus at low, therapeutically relevant concentrations, the passive permeation is expected to have a limited impact on total uptake of the drugs investigated into the hepatocytes. Analogous to rat hepatocytes, a positive linear correlation was observed between the logarithm of the passive diffusion clearance and  $\text{LogD}_{7,4}$  ( $R^2 = 0.886$ ) (Figure 8C).

**Simultaneous modeling of uptake and metabolism of repaglinide.** Uptake and metabolism of repaglinide were studied in three human hepatocyte donors. The kinetic estimates are summarized in Table 2. In donor HU4122, uptake of repaglinide was investigated in the presence of 1 mM ABT, in order to inhibit phase I metabolism and allow only uptake to be characterized in the modeling process. Repaglinide  $f_{u, \text{cell}}$  value of 0.074 was held constant in the mechanistic model and based on values obtained previously in rat hepatocytes. In donors HU4199 and HU8089, the uptake of repaglinide was studied in absence of ABT and the formation of three metabolites was incorporated in the modeling. Repaglinide cell concentrations were fitted with good precision in all cases, as illustrated in diagnostic goodness of the fit plots shown in the Supplementary Material, Figure S3B. Uptake  $K_{m,u}$  of repaglinide was moderate ( $12.8 \pm 3.4 \mu\text{M}$ ) and consistent among the three hepatocyte donors.  $P_{\text{diff},u}$  was amongst the highest values measured in the current dataset ( $12.7 \pm 3.1 \mu/\text{min}/10^6 \text{ cells}$ ) and no significant difference was observed in this parameter across the donors investigated. Variation in uptake activity resulted in up to 2.4-fold difference between  $\text{CL}_{\text{active},u}$  values measured in HU4122 and the additional donors (HU4199 and HU8089) (Figure 3A). Differences in uptake were reflected in the proportion of total uptake due to active transport over the range of concentrations. In HU4122, active uptake was the predominant process responsible for total uptake over the range of concentrations studied. In HU4199 and HU8089, contribution of active process >70% was observed only for concentrations  $\leq 10 \mu\text{M}$  (Figure 2).

The kinetics of repaglinide metabolite formation was also investigated in donors HU4199 and HU8089. As the uptake experiment was performed without ABT, M2, M4 and repaglinide glucuronide were monitored (Supplemental Figure S1). Kinetics of repaglinide glucuronide formation was best described by a single clearance parameter, whereas formation of M2 and M4 was defined by Michaelis-Menten parameters used to describe potential saturation of metabolism over the range of concentrations studied. Clearance due to the formation of repaglinide glucuronide was low, contributing 21 and 6% to total metabolism in donors HU4199 and HU8089, respectively.  $K_{m,u}$  value for the M2 pathway was 6-fold greater in HU4199 than in HU8089. However, this resulted in only 2.5-fold greater  $CL_{met,M2,u}$ , due to differences in metabolic capacity between the two donors. Overall, metabolic clearances in HU4199 and HU8089 were 1.98 and 3.96  $\mu\text{L}/\text{min}/10^6$  cells, respectively. This was lower than the value obtained in donor HU4122 when measured in a separate depletion assay (6.61  $\mu\text{L}/\text{min}/10^6$  cells - data not shown). Uptake clearances were 17- and 8.5-fold greater than metabolism for donor HU8089 and HU4199, respectively.  $K_{m,M4,u}$  was consistently lower than the uptake  $K_{m,u}$  by on average 2-fold, but the difference to  $K_{m,M2,u}$  was less clear due to donor variation.  $CL_{met,M2}$  was greater in comparison to the metabolic clearances of other metabolites formed, consistent with recent studies in pooled cryopreserved hepatocytes where repaglinide metabolism was monitored in isolation (Sall et al., 2012).

**Inter-individual variability in uptake and metabolism activity between human hepatocyte donors.** Analysis of uptake kinetic data showed  $K_m$  to be the most consistent parameter among the three donors with CV of 10 and 27% for rosuvastatin and repaglinide, respectively (Tables 2 and 3).  $P_{diff,u}$  was also similar between the three donors (CV 47 and 24% for rosuvastatin and repaglinide, respectively) consistent with the reliance of passive permeation on lipophilicity of the drugs studied. However, for both drugs, uptake activity varied between the donors, as HU4122 uptake activity was up to 2.4- and 6.8-fold greater than

activity observed in the two other donors for repaglinide and rosuvastatin, respectively (Figure 3).

To explore the use of uptake estimates obtained at a single low concentration in donors HU4199 and HU8089,  $CL_{\text{active,u}}$  for pitavastatin, valsartan, bosentan, pravastatin and telmisartan was estimated using the uptake rate data generated at 1  $\mu\text{M}$  (10  $\mu\text{M}$  for pravastatin) over 2 min only. Uptake  $K_m$  and  $P_{\text{diff}}$  were assumed to be consistent among donors based on full kinetic profiles for repaglinide and rosuvastatin. Keeping these parameters constant in the mechanistic model allowed fitting of the  $V_{\text{max}}$  and subsequent estimation of the  $CL_{\text{active,u}}$ . This approach allowed the delineation of active and passive uptake from a single concentration experiment in a mechanistic manner, using only a fraction of the number of cells required to investigate the full uptake kinetics of a drug. For validation purposes, same analysis was performed in HU4122 and estimates based on this approach were compared to the  $CL_{\text{active,u}}$  obtained from the full kinetic profile in the same donor; the analysis was also carried out for rosuvastatin in all three human hepatocyte donors. As illustrated in Figure 4, the  $CL_{\text{active,u}}$  values obtained using single concentration data were within two-fold of the value generated from the full kinetic profile for all drugs. In the case of pravastatin, as the concentration used (10  $\mu\text{M}$ ) was greater than uptake  $K_{m,u}$ ,  $CL_{\text{active,u}}$  could not be estimated from single concentration uptake data. Therefore, results presented for this drug are solely based on the full kinetic experiment performed in donor HU4122. Precision of the uptake clearance estimated obtained at the single concentration varied from 22% lower for rosuvastatin in donor HU8089 to 47% higher for bosentan in donor HU4122, but overall no significant bias was observed ( $gmfe = 1.2$ ). This approach was therefore considered suitable to estimate  $CL_{\text{active,u}}$  in donors HU4199 and HU8089 from single low concentration data.

Donor HU4122 showed higher uptake activity compared to HU4199 and HU8089 for all drugs investigated, with the exception of bosentan and pitavastatin (Figure 5). On average, uptake clearance in this donor was 2.3- and 2.8-fold greater than in HU4199 and HU8089,

respectively. The greatest difference between donors was observed for rosuvastatin. For this drug, uptake clearance in HU4122 was 5.4- and 6.8-fold greater than in HU4199 and HU8089. On the other hand, uptake of telmisartan was consistent between the three donors, with a CV of only 7.8%. Overall, HU4199 and HU8089 showed similar levels of uptake activity. Uptake clearances in these donors were within 30% of each other for all drugs, with the exception of pitavastatin and bosentan when uptake clearances in HU4199 were 1.9-fold greater than in HU8089. This difference between the three donors was reflected in the uptake of rosuvastatin when this drug was used as a positive control at 1  $\mu\text{M}$  (Figure 6A). However, the use of estrone-3-sulfate at 1  $\mu\text{M}$  did not distinguish three donors in their uptake activity, as the differences seen were not statistically significant ( $p=0.35$ ) (Figure 6B). In addition to current data, uptake clearance values for estrone-3-sulfate were collated from BD Gentest characterization spreadsheets for 28 individual human hepatocyte donors (details shown in Supplementary Material Table S1). Clearances ranged from 4 to 35.5  $\mu\text{L}/\text{min}/10^6$  cells with a mean clearance of  $21.4 \pm 8.5$   $\mu\text{L}/\text{min}/10^6$  cells (CV 40%). No correlation was observed between uptake activity and either gender or age for this dataset (Supplementary Material Figure S4). Mean  $\text{CL}_{\text{uptake}}$  of estrone-3-sulfate in the current study ( $19.5 \pm 7.7$   $\mu\text{L}/\text{min}/10^6$  cells) was comparable to the mean value obtained from this larger dataset ( $p=0.48$ ).

Metabolism of telmisartan was studied in all three donors. Unbound metabolic clearance of telmisartan in HU4122 was 22-fold lower than the active uptake clearance (Table 1). However, metabolic clearance obtained in this donor was 6-fold greater than the values measured in the other two donors (4.3 vs. 0.7  $\mu\text{L}/\text{min}/10^6$  cells, respectively). Although this could be due to variability in metabolic capacity between the donors, it is noteworthy that telmisartan glucuronide was monitored in the entire incubation (cell and media), in the metabolite formation assay carried out in donor HU4122, while it was only measured in the cell in the uptake assay in donors HU4199 and HU8089, as this metabolite could not be detected in the media.

**Prediction of hepatic clearance in human.** Comparison of the observed and predicted hepatic intrinsic clearances for six of the drugs investigated is shown in Figure 7. The importance of active uptake on the prediction of  $CL_{int,h}$  was drug dependent. In the case of pravastatin, rosuvastatin, telmisartan and valsartan, hepatic clearance was mainly driven by  $CL_{active,u}$ , as the combined  $CL_{met,u}$  and  $CL_{bile,u}$  were much greater than  $P_{diff,u}$ . For bosentan and repaglinide,  $CL_{int,u}$  was a composite of a number of processes, as passive diffusion was greater than metabolic and biliary clearances combined. In vitro-in vivo extrapolation of these data resulted in systematic under-prediction of hepatic intrinsic clearance for all drugs in the dataset, with the exception of valsartan which was predicted within two-fold of the observed data. The extent of the under-prediction was compound- and donor-dependent, ranging from 5-fold for pravastatin in donor HU4122 to 66-fold for rosuvastatin in donor HU8089. Hence, the empirical scaling factors for  $CL_{active}$  per individual donor were necessary to recover the observed clearance in vivo and also resulted in a large variation (Table 4). For example, clearances in donor HU4122 were corrected by a factor of 6.9 on average, while values of 25.0 and 25.6 were required in donors HU4199 and HU8089, respectively. Nine out of 16  $CL_{int,u}$  values were predicted within 2-fold of the observed data (Figure 7A). The approach involving empirical scaling factors resulted in low overall bias (2.3), but poor precision (rmse of 801).

In addition, the whole dataset was considered to accommodate both drug and donor variability, resulting in an average empirical scaling factor of 17.1. Use of this approach resulted in 8 out of 16 values predicted within 2-fold, improved precision (rmse of 471) and comparable bias to the previous scenario (gmfe 2.52) (Figure 7B). In all analyses,  $CL_{int,u}$  of valsartan was predicted to be more than 5-fold greater than the observed  $CL_{int,h}$  value. In general, use of the average dataset scaling factor resulted in an over-prediction of clearance when data from donor HU4122 were used (with the exception of bosentan) and under-prediction when using clearances from donors HU4199 and HU8089.

**Comparison between uptake in rat and human hepatocytes.** Uptake kinetic parameters of the seven drugs investigated in the present study were estimated previously in rat hepatocytes using a mechanistic modeling approach (Ménochet et al., 2012).  $K_{m,u}$  were on average 4.3-fold greater in rat compared to human hepatocytes, mainly due to pitavastatin and pravastatin higher affinity towards human transporters (labeled as 1 and 2 in Figure 8A). Valsartan and bosentan were the only drugs in the dataset showing the opposite trend with higher affinity in rat hepatocytes. Pitavastatin had the lowest  $K_{m,u}$  in human hepatocytes (1.59  $\mu\text{M}$ ), while telmisartan showed the highest affinity in rat hepatocytes (2.03  $\mu\text{M}$ ). Pravastatin and bosentan showed the lowest affinity towards rat and human transporters with  $K_{m,u}$  of 37.0 and 22.5  $\mu\text{M}$  in rat and human hepatocytes, respectively. Less than a two-fold difference was observed between  $K_{m,u}$  in rat and human hepatocytes for telmisartan, rosuvastatin, valsartan and bosentan. Overall, the drugs studied covered a similar range of affinity in both species: 11- vs. 14-fold in rat and human, respectively. Despite the greater affinity observed in human hepatocytes, uptake clearances were on average 7.1-fold greater in rat compared to human hepatocytes, due to a large difference in activity between the two species (Figure 8B). The greatest difference was observed for valsartan and rosuvastatin for which  $CL_{\text{active,u}}$  were 16- and 21-fold greater in rat than in human hepatocytes, respectively. All other drugs had  $CL_{\text{active,u}}$  within 5-fold of each other in the two species. The lowest uptake clearance was observed for valsartan in human (1.64  $\mu\text{L}/\text{min}/10^6$  cells) and for pravastatin in rat hepatocytes (12.5  $\mu\text{L}/\text{min}/10^6$  cells). Telmisartan showed the greatest extent of active uptake in human hepatocytes with  $CL_{\text{active,u}}$  of 95.2  $\mu\text{L}/\text{min}/10^6$ , while active uptake of repaglinide was the greatest in rat hepatocytes (119  $\mu\text{L}/\text{min}/10^6$  cells). Therefore,  $CL_{\text{active,u}}$  covered a wider range in human than in rat hepatocytes: 53- vs. 8-fold, respectively. As anticipated, inter-individual variability in uptake clearance was greater in human compared to rat hepatocytes for all drugs excluding telmisartan.



Unlike active uptake, passive diffusion clearance was consistent between the two species, with  $P_{\text{diff,u}}$  in rat being only 1.7-fold greater on average than in human hepatocytes (Figure 8C). However,  $P_{\text{diff,u}}$  values obtained for the poorly permeable compounds were much lower in human compared to rat cells, whereas the  $P_{\text{diff,u}}$  values at the higher end were comparable between the two species (21.4 and 14.1  $\mu\text{L}/\text{min}/10^6$  cells for telmisartan in rat and human hepatocytes, respectively);  $P_{\text{diff,u}}$  values in human span 222-fold while they only covered a 60-fold range in rat hepatocytes.  $P_{\text{diff,u}}$  in human hepatocytes was positively correlated with  $\text{LogD}_{7.4}$ , consistent with the previous analyses in rat hepatocytes. At low concentrations, active transport was the major process driving total uptake for all drugs in both species.

A large difference in telmisartan metabolism was observed between rat and human hepatocytes; glucuronidation clearance was 32-fold greater in rat compared to human hepatocytes. Metabolic clearance was only 4-fold lower than active uptake in rat, whereas the difference between these two processes was up to 71-fold in human hepatocytes depending on the individual donor. In contrast, repaglinide glucuronidation and overall metabolism data were more consistent between the two species in comparison to telmisartan. Yet, species differences were evident, as the formation of M2 was increased by 5-fold between rat and human hepatocytes. In addition, M4 metabolite was not identified as a major metabolite in rat hepatocytes, but a clearance of 1.26  $\mu\text{L}/\text{min}/10^6$  cells was measured in human. These differences resulted in a repaglinide total metabolic clearance in human 4-fold greater than in rat. Total metabolic clearance was lower than the active uptake in both species; however, this difference was 13-fold on average in human hepatocytes in contrast to 112-fold reported for the rat data (Ménochet et al., 2012), probably reflecting the differences in uptake activity between the two species.

## Discussion

A mechanistic two-compartment model, previously developed in rat hepatocytes was applied here for the analysis of human hepatocyte data, allowing description of the interplay between active uptake, passive diffusion, intracellular binding and metabolism. Uptake kinetics of seven OATP substrates was investigated in three human hepatocyte donors using a standardized experimental method and modeling approach. The data generated were applied for the prediction of in vivo hepatic clearance and comparison with previously obtained parameters in rat hepatocytes.

The seven drugs investigated showed a 14-fold range in  $K_{m,u}$  values (Figure 8A), but due to greater variation in their uptake capacity,  $CL_{active,u}$  ranged 34-fold (Figure 8B). The  $CL_{active,u}$  values presented here are generally consistent with literature data. However, higher uptake clearances have been reported for pitavastatin and valsartan (Hirano et al., 2004; Poirier et al., 2009), whereas the opposite was observed for pravastatin and telmisartan (Nakai et al., 2001; Ishiguro et al., 2006). Discrepancies observed may be associated with inconsistencies in the uptake experimental design (use of single concentration vs. full kinetic profile) and data analysis amongst the studies published to date. Uptake activity and passive diffusion were both correlated with lipophilicity, as was the extent of intracellular binding; however, no correlation could be established between  $CL_{uptake,u}$  and  $K_{m,u}$ ,  $\text{LogD}_{7.4}$  or  $f_{u,cell}$ . Unlike the approach traditionally used to analyze in vitro uptake data, the mechanistic two-compartment model provides an insight into the effect of the bidirectional passive diffusion over a range of concentrations. At low concentrations, the passive diffusion had limited contribution to the overall uptake for all drugs investigated (Figure 2), which is of relevance as the unbound  $C_{max}$  (following therapeutic dose) of the drugs studied ranges from 0.80 nM to 0.52  $\mu\text{M}$  for pitavastatin and valsartan, respectively (Sunkara et al., 2007; Deng et al., 2008). However, as these drugs are administered orally, concentrations in the hepatic portal vein could be higher and the contribution of passive processes may differ.

The  $f_{u,cell}$  term in the mechanistic uptake model was based on studies in rat hepatocytes following an extended incubation time (45-90 min) to allow a steady state between intracellular concentration and media to be reached. Use of these  $f_{u,cell}$  values allowed a reasonably precise estimation of kinetic parameters for all drugs (CV<30%, with the exception of pravastatin), despite the reduced number of data points available for analysis compared to rat hepatocytes. This insight into the extent of intracellular binding also permitted the simultaneous assessment of uptake and metabolism, giving a further understanding of the interplay between these two processes compared to previous studies (Paine et al., 2008; Poirier et al., 2008; Watanabe et al., 2009). In the case of repaglinide, active uptake was on average 4.3- and 13-fold greater than passive diffusion and metabolic clearances, respectively. Consistent with the rat data, active uptake has been identified as the major contributor to repaglinide overall clearance. However, a significant contribution of the passive component to the total uptake should not be neglected, as supported by only 2.4-fold increase in repaglinide AUC when co-administered with cyclosporine (potent OATP1B1 inhibitor) (Kajosaari et al., 2005; Amundsen et al., 2010). Considering that metabolism represents the rate-limiting process for repaglinide hepatic clearance, one may expect that the DDIs observed for this type of drug would be metabolism driven. However, such interpretation of the current findings is inappropriate for inhibitors showing dual effects on uptake transporters and metabolism, as illustrated in repaglinide-gemfibrozil/gemfibrozil glucuronide interaction leading to marked increase in repaglinide exposure (Niemi et al., 2003). The data analysis presented here provides a mechanistic description of the processes occurring in the hepatocytes that should improve our ability to quantitatively predict risk of complex DDIs involving both uptake and metabolism.

Analogous to  $K_{m,u}$ , passive diffusion clearances showed minimal donor dependence, although no correlation was evident between  $K_{m,u}$  and  $P_{diff}$ . Consistency in these parameters across donors allowed the use of the mechanistic two-compartment model to successfully

estimate  $CL_{\text{active,u}}$  from experiments carried out at a single concentration. Although this approach requires prior knowledge of  $K_{\text{m,u}}$  and  $P_{\text{diff,u}}$ , it permits the investigation of inter-individual variability from a reduced number of human cells, while allowing the mechanistic nature of the data analysis. Although donor HU4122 exhibited the greatest uptake capacity overall, drugs investigated showed very different extent of uptake depending on the donor used. Rosuvastatin demonstrated the greatest variability in uptake clearance between donors with a CV of 108% (Table 3), reflecting the variability in uptake  $V_{\text{max}}$  (CV 111%). Similar trend was more evident for drugs with predominant active uptake in the current dataset. Comparable degree of inter-individual variability has been reported previously (Ishiguro et al., 2006; Yamada et al., 2007). While Yamada et al. (2007) found a variation of 10% in olmesartan uptake clearance between three donors, Ishiguro et al. (2006) found CV as high as 68% when they investigated the clearance of estradiol-17 $\beta$ -glucuronide in three donors. Emerging absolute quantification data of uptake transporter expression in a number of human livers support this inter-individual variability (Ohtsuki et al., 2012). However, the extent to which this variability in transporter expression in the actual tissue relates to the inter-individual variability in uptake activity in isolated human hepatocytes remains to be established.

In vitro-in vivo extrapolation resulted in systematic under-prediction of hepatic intrinsic clearances, as in some instances predicted values represented <2% of the observed data (rosuvastatin in donor HU8089). Inter-individual variability observed in uptake activity resulted in drug and donor-specific empirical scaling factors, ranging from 6.9-25.6 (Table 4). Overall, scaling factors required here were greater than the values reported previously (3.7-6.5) for rat plated hepatocytes and estimated for individual drugs or small datasets (Poirier et al., 2009; Watanabe et al., 2009; Gardiner and Paine, 2011). This species difference in prediction success is also evident for metabolic clearance based on large datasets (Ito and Houston, 2005). These results also emphasize the difficulty one faces when trying to identify

suitable human hepatocyte donors to investigate the uptake of NCEs. Considering the large range in individual empirical scaling factors and compound differences, it is not surprising that the use of an average factor of 17.1 was not satisfactory for some drugs and in particular for data obtained in HU4122 donor. These findings emphasize the need to characterize human hepatocytes against a set of uptake markers to allow prediction of the impact of active uptake on NCE pharmacokinetics in human.

Giacomini et al. (2010) recommended the use of rosuvastatin, pravastatin or pitavastatin as probes to study DDIs involving OATP1B1 in vivo. In the present study, we have investigated whether these drugs could be used as markers of variability in uptake activity across different hepatocyte donors. Pravastatin exhibited limited ionization when analyzed by LC-MS/MS and reliable results could not be generated in all hepatocyte donors. Unlike the general trend observed in the dataset, pitavastatin showed greater active uptake in donor HU4199 than in HU4122 (Figure 5). This could be due to the fact that pitavastatin is almost exclusively transported by OATP1B1 (Hirano et al., 2004) and uptake of this compound therefore reflects only variability in a single transporter. Rosuvastatin uptake was a good marker of observed inter-individual variability in uptake activity regardless whether full kinetics or a single concentration was used. A significant difference was observed between donors HU4122 and HU8089 when uptake was measured at 1  $\mu$ M as a control ( $p < 0.05$ ) but not between HU4122 and HU4199. Rosuvastatin is transported not only by OATP1B1 and OATP1B3, but also by NTCP (Ho et al., 2006; Kitamura et al., 2008). Therefore, uptake clearance of rosuvastatin might reflect better the overall uptake capabilities of cells, despite its limited application as a specific marker of OATP1B1 activity.

The final aim of this study was to investigate differences between uptake in rat and human hepatocytes.  $K_{m,u}$  values in both species were within 2-fold for all drugs studied (Figure 8A), with the exception of pravastatin and pitavastatin, despite the differences in OATPs expressed (Hagenbuch and Gui, 2008). Similarly,  $P_{diff}$  was consistent between the two

species, showing on average less than a 2-fold difference. The greatest inter-species differences were observed for  $CL_{\text{active,u}}$ , as this parameter was on average 7-fold greater in rat compared to human hepatocytes, with rosuvastatin and valsartan exhibiting differences of up to 21-fold (Figure 8B). Although this difference could be explained by variation in transporter expression and specificity between the two species, it is noteworthy that while rat hepatocytes were freshly isolated, human cryopreserved hepatocytes were used. Uptake activity has been shown to decrease after cryopreservation and over time in culture (Badolo et al., 2011; Ulvestad et al., 2011). Therefore, although rat hepatocytes can be a useful surrogate for human cells when developing the experimental method, the discrepancy in transporter expression and specificity occurring naturally or as a result of the isolation/storage techniques confounds direct scaling of clearances obtained in rat hepatocytes to human.

In conclusion, a mechanistic two-compartment model was applied to uptake experiments carried out in human hepatocytes to simultaneously estimate active uptake, passive diffusion, intracellular binding and metabolism. Although the affinity of the drugs towards the transporter proteins remained constant, large variability were observed in uptake activity between the three human hepatocyte donors investigated. Uptake activity differed between rat and human hepatocytes; however, information obtained in rat hepatocytes on the extent of intracellular binding was essential for the modeling of the human hepatocytes data and for more informative experimental design of uptake studies in human hepatocytes with reduced number of concentration/time points. Under-prediction of hepatic intrinsic clearances emphasizes the need to account for differences in both transporter expression and activity between hepatocytes and liver tissue and variability associated.

### **Acknowledgements**

We acknowledge the assistance of Dr. David Hallifax and Sue Murby with the LC-MS/MS analysis and Dr Michael Gertz (all University of Manchester) for his help with the modeling of uptake data.

**Authorship contribution**

Participated in research design: Galetin, Houston, Kenworthy, Ménochet

Conducted experiments: Ménochet

Contributed new reagents or analytic tools: Not applicable

Performed data analysis: Ménochet, Galetin

Wrote or contributed to the writing of the manuscript: Ménochet, Houston and Galetin



## References

- Amundsen R, Christensen H, Zabihyan B and Asberg A (2010) Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. *Drug Metab Dispos* **38**:1499-1504.
- Badolo L, Trancart MM, Gustavsson L and Chesne C (2011) Effect of cryopreservation on the activity of OATP1B1/3 and OCT1 in isolated human hepatocytes. *Chem Biol Interact* **190**:165-170.
- Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS and Hansen KT (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. *Br J Clin Pharmacol* **56**:305-314.
- Bow DA, Perry JL, Miller DS, Pritchard JB and Brouwer KL (2008) Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes. *Drug Metab Dispos* **36**:198-202.
- Brown HS, Griffin M and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. *Drug Metab Dispos* **35**:293-301.
- Chiba M, Ishii Y and Sugiyama Y (2009) Prediction of hepatic clearance in human from in vitro data for successful drug development. *AAPS J* **11**:262-276.
- De Bruyn T, Ye ZW, Peeters A, Sahi J, Baes M, Augustijns PF and Annaert PP (2011) Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. *Eur J Pharm Sci* **43**:297-307.
- Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH and Shin JG (2008) The effect of SLCO1B1\*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1\*15. *Pharmacogenet Genomics* **18**:424-433.
- Fujino H, Yamada I, Shimada S, Yoneda M and Kojima J (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. *Xenobiotica* **33**:27-41.
- Gardiner P and Paine SW (2011) The Impact of Hepatic Uptake on the Pharmacokinetics of Organic Anions. *Drug Metab Dispos* **39**:1930-1938.
- Gertz M, Harrison A, Houston JB and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. *Drug Metab Dispos* **38**:1147-1158.
- Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ and Zhang L (2010) Membrane transporters in drug development. *Nat Rev Drug Discov* **9**:215-236.
- Hagenbuch B and Gui C (2008) Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. *Xenobiotica* **38**:778-801.
- Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. *Pflugers Arch* **447**:653-665.
- Hallifax D, Foster JA and Houston JB (2010) Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. *Pharm Res* **27**:2150-2161.

- Hallifax D and Houston JB (2009) Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems. *Curr Drug Metab* **10**:307-321.
- Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM and Hengstler JG (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. *Drug Metab Rev* **39**:159-234.
- Hirano M, Maeda K, Shitara Y and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. *J Pharmacol Exp Ther* **311**:139-146.
- Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y and Kim RB (2006) Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics. *Gastroenterology* **130**:1793-1806.
- Ieiri I, Higuchi S and Sugiyama Y (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. *Expert Opin Drug Metab Toxicol* **5**:703-729.
- Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T and Sugiyama Y (2006) Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. *Drug Metab Dispos* **34**:1109-1115.
- Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. *Pharm Res* **22**:103-112.
- Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston B, Galetin A and Fenner KS (2012) Mechanistic Pharmacokinetic Modelling for the Prediction of Transporter-mediated Disposition in Human from Sandwich Culture Human Hepatocyte Data. *Drug Metab Dispos* **40**(5):1007-1017.
- Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ and Backman JT (2005) Cyclosporine markedly raises the plasma concentrations of repaglinide. *Clin Pharmacol Ther* **78**:388-399.
- Kitamura S, Maeda K, Wang Y and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. *Drug Metab Dispos* **36**:2014-2023.
- Kotani N, Maeda K, Watanabe T, Hiramatsu M, Gong LK, Bi YA, Takezawa T, Husuhara H and Sugiyama Y (2011) Culture-period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes. *Drug Metab Dispos* **39**:1503-1510.
- Landaw EM and DiStefano JJ, 3rd (1984) Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. *Am J Physiol* **246**:R665-677.
- Lave T, Coassolo P, Ubeaud G, Brandt R, Schmitt C, Dupin S, Jaeck D and Chou RC (1996) Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. *Pharm Res* **13**:97-101.
- Martignoni M, Groothuis GM and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. *Expert Opin Drug Metab Toxicol* **2**:875-894.
- Ménochet K, Kenworthy K, Houston JB and Galetin A (2012) Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. *J Pharmacol Exp Ther*. **341** (1):2-15.

- Mico BA, Federowicz DA, Ripple MG and Kerns W (1988) In vivo inhibition of oxidative drug metabolism by, and acute toxicity of, 1-aminobenzotriazole (ABT). A tool for biochemical toxicology. *Biochem Pharmacol* **37**:2515-2519.
- Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T and Nishimura K (2001) Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. *J Pharmacol Exp Ther* **297**:861-867.
- Nakakariya M, Shimada T, Irokawa M, Maeda T and Tamai I (2008) Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. *Drug Metab Pharmacokinet* **23**:347-355.
- Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT and Neuvonen PJ (2005) Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. *Clin Pharmacol Ther* **77**:468-478.
- Niemi M, Backman JT, Neuvonen M and Neuvonen PJ (2003) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. *Diabetologia* **46**:347-351.
- Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Sato A, Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, Ebner T and Terasaki T (2012) Simultaneous Absolute Protein Quantification of Transporters, Cytochrome P450s and UDP-glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities. *Drug Metab Dispos* **40**:83-92.
- Paine SW, Parker AJ, Gardiner P, Webbhorn PJ and Riley RJ (2008) Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. *Drug Metab Dispos* **36**:1365-1374.
- Parker AJ and Houston JB (2008) Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. *Drug Metab Dispos* **36**:1375-1384.
- Plise EG, Halladay JS, Cheong J, Sodhi J and Salphati L (2010) Commonly used inhibitors of drug metabolizing enzymes: do they also inhibit drug transporters? *Drug Metabolism Reviews* **42**:139.
- Poirier A, Cascais AC, Funk C and Lave T (2009) Prediction of Pharmacokinetic Profile of Valsartan in Humans Based on in vitro Uptake-Transport Data. *Chem Biodivers* **6**:1975-1987.
- Poirier A, Lave T, Portmann R, Brun ME, Senner F, Kansy M, Grimm HP and Funk C (2008) Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. *Drug Metab Dispos* **36**:2434-2444.
- Reinoso RF, Telfer BA, Brennan BS and Rowland M (2001) Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. *Drug Metab Dispos* **29**:453-459.
- Sall C, Houston JB and Galetin A (2012) A Comprehensive Assessment of Repaglinide Metabolic Pathways: Impact of Choice of In Vitro System and Relative Enzyme Contribution to In Vitro Clearance. *Drug Metab Dispos*.
- Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. *Pharmacol Ther* **112**:71-105.
- Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS and Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant recipients

- administered an antirejection regimen including cyclosporine. *Clin Pharmacol Ther* **76**:167-177.
- Soars MG, Grime K, Sproston JL, Webborn PJ and Riley RJ (2007) Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. *Drug Metab Dispos* **35**:859-865.
- Stangier J, Schmid J, Turck D, Switek H, Verhagen A, Peeters PA, van Marle SP, Tamminga WJ, Sollie FA and Jonkman JH (2000) Absorption, metabolism, and excretion of intravenously and orally administered [<sup>14</sup>C]telmisartan in healthy volunteers. *J Clin Pharmacol* **40**:1312-1322.
- Sunkara G, Reynolds CV, Pommier F, Humbert H, Yeh C and Prasad P (2007) Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. *Curr Med Res Opin* **23**:631-640.
- Ulvestad M, Bjorquist P, Molden E, Asberg A and Andersson TB (2011) OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. *Biochem Pharmacol* **82**:1219-1226.
- Watanabe T, Kusuhara H, Maeda K, Shitara Y and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. *J Pharmacol Exp Ther* **328**:652-662.
- Yabe Y, Galetin A and Houston JB (2011) Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. *Drug Metab Dispos* **39**:1808-1814.
- Yamada A, Maeda K, Ishiguro N, Tsuda Y, Igarashi T, Ebner T, Roth W, Ikushiro S and Sugiyama Y (2011) The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. *Pharmacogenet Genomics* **21**:523-530.
- Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y, Nakazawa H, Okano T, Adachi M, Schuetz JD, Adachi Y, Hu Z, Kusuhara H and Sugiyama Y (2007) Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. *Drug Metab Dispos* **35**:2166-2176.

### **Footnotes**

K.M. was supported by a PhD studentship from GlaxoSmithKline, Ware, UK and the Biotechnology and Biological Sciences Research Council, UK.

Part of this work was presented at the 9<sup>th</sup> International ISSX meeting in Istanbul, Turkey, September 4-8, 2010.

## Figure legends

**Figure 1:** Extended two-compartment model (Equations 6-9) describing the uptake and metabolism of repaglinide in human hepatocytes over time.  $S_{\text{Gluc,cell}}$ ,  $S_{\text{M2,cell}}$  and  $S_{\text{M4,cell}}$  represent concentrations of major repaglinide metabolites in the cell.  $CL_{\text{met,gluc,u}}$  is the glucuronidation clearance;  $K_{\text{m,M2,u}}$ ,  $V_{\text{max,M2}}$ ,  $K_{\text{m,M4,u}}$  and  $V_{\text{max,M4}}$  are the Michaelis-Menten parameters describing the concentration dependent saturation of the formation of M2 and M4. In the case of telmisartan, the model was limited to the parent compound and the glucuronide metabolite.

**Figure 2:** Proportion of total uptake due to active transport and passive diffusion in human hepatocytes over a range of concentrations. Active transport and passive diffusion were estimated over the range of concentration studied using either a generic or extended two-compartment mechanistic model based on uptake kinetic estimates obtained in human hepatocyte donors HU4122 (black line), HU4199 (red line) and HU8089 (green line). Solid line represents the proportion of active transport; dashed line represents the proportion of passive diffusion. A: Rosuvastatin; B: Repaglinide; C: Bosentan; D: Pitavastatin; E: Pravastatin; F: Telmisartan; G: Valsartan.

**Figure 3:** Total uptake kinetic profiles of repaglinide (A) and rosuvastatin (B) measured in three batches of cryopreserved human hepatocyte plated for 6 hr. Data represent the mean of uptake rates measured in duplicate at 2 min in donor HU4122 (●), HU4199 (○) and HU8089 (●). Six concentrations were used for repaglinide (0.1-100  $\mu\text{M}$ ), seven for rosuvastatin (0.1-300  $\mu\text{M}$ ). Lines represent the simulated total uptake based on uptake kinetic estimates obtained from the two-compartment mechanistic model, including metabolism in the case of repaglinide.

**Figure 4:** Comparison between uptake clearances obtained from full kinetic experiments in human hepatocytes and value estimated based on data generated at 1  $\mu\text{M}$  only using mechanistic model.

**Figure 5:** Active uptake clearance of 6 OATP substrates in human hepatocyte donors generated using a full kinetic approach (HU4122 (●)) or extrapolated from measurements at 1  $\mu\text{M}$  (HU4199 (○) and HU8089 (●)). Line represents the mean of the three clearance estimates.

**Figure 6:** Uptake clearances of rosuvastatin (A) and estrone-3-sulfate (B) measured as a control in human hepatocyte donors HU4122 (n=8), HU4199 (n=3) and HU8089 (n=4) at 1  $\mu\text{M}$ . — represents the median, □ the mean, box represents the 25th and 75th percentiles, whiskers are 5th and 95th percentiles.

**Figure 7:** Comparison of predicted and observed hepatic clearances for the drugs investigated. Scaling factors were based either on the donor-specific (A) or empirical scaling factors obtained using the whole dataset (B). Hepatic clearance was predicted from uptake, metabolic and passive diffusion clearances obtained in three human hepatocyte donors and the biliary clearance values reported in the literature. ● represents bosentan, ○ pravastatin, ■ repaglinide, □ rosuvastatin, ▲ telmisartan, △ valsartan. Solid line is the line of unity. Dashed and dotted lines are for 2- and 5-fold difference.

**Figure 8:** Comparison of the uptake affinity (A) active uptake clearance (B) and passive diffusion clearance (C) of 7 OATP substrates in rat and human hepatocytes.  $K_{m,u}$ ,  $CL_{active,u}$  and  $P_{diff,u}$  estimates in rat hepatocytes were obtained from full kinetic experiments for all drugs. Data represent the mean  $\pm$  SD of three experiments.  $K_{m,u}$  and  $P_{diff,u}$  in human hepatocytes were

obtained from full kinetic experiments in donor HU4122, with the exception of rosuvastatin and repaglinide where full kinetic experiments were conducted in all three human hepatocyte donors.  $CL_{\text{active,u}}$  in human are the mean  $\pm$  SD of estimates obtained from the full kinetic experiment in donor HU4122 and extrapolated from experiments conducted at 1  $\mu\text{M}$  in donors HU4199 and HU8089. In panels A and B, solid line represents the line of unity; dashed lines are for 2-fold difference. In panel C, solid line represents the line of best fit between  $\text{LogD}_{7.4}$  and the passive diffusion clearances generated in human hepatocytes. ● represents data generated in human hepatocytes and ○ data obtained in rat hepatocytes. 1- pitavastatin, 2- pravastatin, 3- telmisartan, 4- repaglinide, 5- rosuvastatin, 6- valsartan, 7- bosentan.



TABLE 1

*Uptake kinetic parameters of 7 OATP substrates estimated in human hepatocyte using a mechanistic two-compartment model. Uptake kinetics was measured in cryopreserved human hepatocytes (donor HU4122) plated for 6 hr over 2 min at 7 concentrations (0.1 - 300  $\mu$ M).*

<b>Drug</b>	<b>K<sub>m,u</sub></b> ( $\mu$ M)	<b>V<sub>max</sub></b> (pmol/min/10 <sup>6</sup> cells)	<b>P<sub>diff,u</sub></b> ( $\mu$ L/min/10 <sup>6</sup> cells)	<b>fu<sub>cell</sub><sup>a</sup></b>	<b>fu<sub>med</sub></b>	<b>CL<sub>active,u</sub></b> ( $\mu$ L/min/10 <sup>6</sup> cells)
Bosentan	22.5	402	9.74	0.096	0.85	17.9
Pitavastatin	1.59	65	13.2	0.053	0.63	40.7
Pravastatin	2.25	6.24	0.208	0.963	0.91	2.77
Repaglinide	15.6	1236	10.0	0.074	0.95	79.0
Rosuvastatin	11.2	104	0.391	0.477	0.93	9.21
Telmisartan <sup>b</sup>	2.03	193	14.1	0.024	0.71	95.2
Valsartan	10.4	30	0.064	1	1	2.88

<sup>a</sup>Data from uptake experiments performed in rat hepatocytes (Ménochet et al., 2012).

<sup>b</sup>Kinetics parameters obtained when telmisartan metabolism was incorporated to the modeling (CL<sub>met</sub> = 4.3  $\mu$ L/min/10<sup>6</sup> cells)

TABLE 2

*Uptake and metabolism kinetic parameters of repaglinide estimated in 3 human hepatocyte donors using an extended mechanistic two-compartment model*

<b>Donor</b>	<b>HU4122</b>	<b>HU4199</b>	<b>HU8089</b>	<b>Mean</b>
$K_{m,u}$ ( $\mu\text{M}$ )	15.6	8.97	13.8	$12.8 \pm 3.4$
$V_{\max}$ ( $\text{pmol}/\text{min}/10^6$ cells)	1236	310	464	$670 \pm 496$
$P_{\text{diff},u}$ ( $\mu\text{L}/\text{min}/10^6$ cells)	10.0	16.0	12.0	$12.7 \pm 3.1$
$f_{u_{\text{cell}}}$ <sup>a</sup>	0.074	0.074	0.074	0.074
$f_{u_{\text{med}}}$	0.95	0.94	0.96	$0.95 \pm 0.01$
$CL_{\text{active},u}$ ( $\mu\text{L}/\text{min}/10^6$ cells)	79.0	34.6	33.6	$49.1 \pm 25.9$
$CL_{\text{met,gluc},u}$ ( $\mu\text{L}/\text{min}/10^6$ cells)	-	0.412	0.242	0.327
$K_{m,M2,u}$ ( $\mu\text{M}$ )	-	41.5	7.40	24.4
$CL_{\text{met},M2,u}$ ( $\mu\text{L}/\text{min}/10^6$ cells)	-	0.950	2.42	1.68
$K_{m,M4,u}$ ( $\mu\text{M}$ )	-	5.32	8.83	7.07
$CL_{\text{met},M4,u}$ ( $\mu\text{L}/\text{min}/10^6$ cells)	-	0.619	1.29	0.957
$CL_{\text{met,total},u}$ ( $\mu\text{L}/\text{min}/10^6$ cells)	-	1.98	3.96	2.97

Uptake kinetics was measured in cryopreserved human hepatocytes plated for 6h at 7 concentrations (0.1 - 300  $\mu\text{M}$ ) in the presence (HU4122) or absence (HU4199 and HU8089) of 1 mM ABT.

<sup>a</sup>Data from uptake experiments performed in rat hepatocytes over extended incubation time (Ménochet et al., 2012).

TABLE 3

*Uptake kinetic parameters of rosuvastatin estimated in 3 human hepatocyte donors using a mechanistic two-compartment model. Uptake kinetics was measured in cryopreserved human hepatocytes plated for 6 hr over 2 min at 7 concentrations (0.1 - 300  $\mu$ M).*

<b>Donor</b>	<b><math>K_{m,u}</math></b> ( $\mu$ M)	<b><math>V_{max}</math></b> (pmol/min/ $10^6$ cells)	<b><math>P_{diff,u}</math></b> ( $\mu$ L/min/ $10^6$ cells)	<b><math>fu_{med}</math></b>	<b><math>CL_{active,u}</math></b> ( $\mu$ L/min/ $10^6$ cells)
HU4122	11.2	104	0.391	0.80	9.21
HU4199	9.80	16.6	0.148	1	1.69
HU8089	12.0	16.3	0.243	0.96	1.35
Mean $\pm$ SD	11.0 $\pm$ 1.1	45.5 $\pm$ 50.3	0.261 $\pm$ 0.123	0.93 $\pm$ 0.13	4.09 $\pm$ 4.44

TABLE 4

*Empirical scaling factors applied to the active uptake clearances in order to recover the intrinsic uptake clearance in human livers*

Human hepatocyte donor	HU4122	HU4199	HU8089	
Drug	Scaling factors			Mean
Bosentan	16.1	13.0	24.8	17.9 ± 6.1
Pravastatin	6.67	ND	ND	6.67
Repaglinide	4.70	39.2	17.7	20.5 ± 17.4
Rosuvastatin	9.75	51.9	65.3	42.3 ± 29.0
Telmisartan	3.23	18.7	17.9	13.3 ± 8.7
Valsartan	0.740	2.00	2.20	1.64 ± 0.79
Mean	6.87 ± 5.46	25.0 ± 20.2	25.6 ± 23.7	17.1 ± 18.8

ND: Not determined, as  $CL_{\text{uptake,u}}$  could not be measured accurately at a single concentration

Figure 1




Figure 2




Figure 3





Figure 4






Figure 5





Figure 6

**A**



**B**




Figure 7








Figure 8



## Supplementary Data

### Use of a mechanistic model to assess inter-individual and inter-species variability in active uptake in human and rat hepatocytes - Drug Metabolism and Disposition (DMD #46193)

K. Ménochet, K.E. Kenworthy, J.B. Houston and A. Galetin

**Table S1:** Uptake clearance of 2  $\mu$ M estrone-3-sulfate and demographic information on 28 human hepatocyte donors. Data were collated from the characterization spreadsheet supplied by BD Gentest between September 2008 and September 2011

Donor ID	Gender	Age (year)	Ethnicity	Estrone-3-sulfate uptake clearance ( $\mu$ L/min/ $10^6$ cells)
HH120	Male	58	Caucasian	17.5
HH127	Male	5	Caucasian	13.5
HH139	Female	47	Caucasian	19.5
HH145	Male	69	Caucasian	29.5
HH157	Female	64	Caucasian	4.45
HH162	Male	42	African American	27
HH171	Male	52	Caucasian	35.5
HH193	Female	3	Native American	18
HH202	Male	0.9	Hispanic	11.5
HH206	Female	49	Caucasian	31
HH209	Male	14	Caucasian	27.5
HH215	Female	0.01	Caucasian	19.5
HH222	Female	48	Caucasian	12
HH225	Male	42	Caucasian	24
HH229	Male	56	Asian	30.5
HH243	Female	32	Caucasian	19.5
HH263	Male	2	Caucasian	26.5
HH266	Female	61	Caucasian	23.5
HH268	Female	54	Caucasian	22.5
HH269	Male	23	Caucasian	17.5
HH293	Female	61	Caucasian	32.5
HH304	Male	58	Caucasian	16
HH314	Male	26	African American	23
HH318	Female	64	Caucasian	35
HFC444	Female	53	Caucasian	30
HMC459	Male	53	Caucasian	14
HFC463	Female	70	Caucasian	4
HFC473	Female	57	Caucasian	14.5

**Table S2:** Literature data used for the comparison between observed and predicted hepatic clearance

<b>Drug</b>	<b>CL<sub>tot</sub></b> <b>(mL/min/kg)</b>	<b>CL<sub>r</sub></b> <b>(mL/min/kg)</b>	<b>CL<sub>bile</sub></b> <b>(mL/min/kg)</b>	<b>fu<sub>p</sub></b>
Bosentan	2.39 <sup>a</sup>	0.0215 <sup>a</sup>	0.0885 <sup>a</sup>	0.02 <sup>b</sup>
Pravastatin	13.5 <sup>c</sup>	6.3 <sup>c</sup>	3.04 <sup>d</sup>	0.554 <sup>e</sup>
Repaglinide	7.76 <sup>f</sup>	0.621 <sup>f</sup>	ND	0.036 <sup>g</sup>
Rosuvastatin	11.6 <sup>h</sup>	3.24 <sup>h</sup>	3.12 <sup>h</sup>	0.12 <sup>i</sup>
Telmisartan	12.3 <sup>j</sup>	0 <sup>k</sup>	12.0 <sup>k</sup>	0.005 <sup>j</sup>
Valsartan	0.521 <sup>l</sup>	0.148 <sup>l</sup>	0.321 <sup>m</sup>	0.059 <sup>n</sup>

**a:** Weber C, Gasser R, and Hopfgartner G (1999) Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. *Drug Metab Dispos* 27:810-815.

**b:** Blanchard N, Alexandre E, Abadie C, Lave T, Heyd B, Manton G, Jaeck D, Richert L, and Coassolo P (2005) Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. *Xenobiotica* 35:1-15.

**c:** Singhvi SM, Pan HY, Morrison RA, and Willard DA (1990) Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. *Br J Clin Pharmacol* 29:239-243.

**d:** Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, and Weinstein SH (1991) Biotransformation of pravastatin sodium in humans. *Drug Metab Dispos* 19:740-748.

**e:** Watanabe T, Kusuvara H, Maeda K, Kanamaru H, Saito Y, Hu Z, and Sugiyama Y (2010) Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. *Drug Metab Dispos* 38:215-222.

**f:** Hatorp V, Oliver S, and Su CA (1998) Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. *Int J Clin Pharmacol Ther* 36:636-641.

**g:** Marbury TC, Ruckle JL, Hatorp V, Andersen MP, Nielsen KK, Huang WC, and Strange P (2000) Pharmacokinetics of repaglinide in subjects with renal impairment. *Clin Pharmacol Ther* 67:7-15.

**h:** Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, and Lenz E (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. *Clin Ther* 25:2822-2835.

**i:** Regulatory documents.

**j:** Stangier J, Su CA, and Roth W (2000) Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. *J Int Med Res* 28:149-167.


**k:** Stangier J, Schmid J, Turck D, Switek H, Verhagen A, Peeters PA, van Marle SP, Tamminga WJ, Sollie FA, and Jonkman JH (2000) Absorption, metabolism, and excretion of intravenously and orally administered [<sup>14</sup>C]telmisartan in healthy volunteers. *J Clin Pharmacol* 40:1312-1322.

**l:** Flesch G, Muller P, and Lloyd P (1997) Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. *Eur J Clin Pharmacol* 52:115-120.

**m:** Waldmeier F, Flesch G, Muller P, Winkler T, Kriemler HP, Buhlmayer P, and De Gasparo M (1997) Pharmacokinetics, disposition and biotransformation of [<sup>14</sup>C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. *Xenobiotica* 27:59-71.


**n:** Colussi DM, Parisot C, Rossolino ML, Brunner LA, and Lefevre GY (1997) Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. *J Clin Pharmacol* 37:214-221.

**Figure S1** Formation of M1 (○), M2 (●), M4 (□) and repaglinide glucuronide (■) in human hepatocytes over 15 min at a range of concentrations (0.1 - 100  $\mu$ M). Metabolite concentrations were monitored in the cells. Data points represent the mean of duplicate measurements carried out in donor HU8089. A comparable profile was observed in donor HU4199.







**Figure S2:** Representative uptake kinetic profiles after 2 min incubation for seven OATP substrates over a range of substrate concentrations based on the mechanistic modeling approach. Total uptake was obtained from measurements at 37°C. Active transport and passive diffusion were delineated from Equation 2. Active uptake was expressed as the difference between total uptake and passive diffusion. Closed symbols and solid lines represent measured and predicted total uptake estimated from kinetic parameters obtained with each approach, respectively. Dashed and dotted lines represent cellular uptake due to active transport and passive diffusion, respectively. Data points are mean of duplicate measurements.



**G**



**Figure S3:** Predicted and observed rosuvastatin (A) and repaglinide (B) cell concentrations when data were analyzed using a mechanistic two-compartment. Each plot represents cell concentrations measured in three experiments, over a range of concentrations (0.1 - 100  $\mu\text{M}$ ), in incubations carried out over 2 min for rosuvastatin and 15 min for repaglinide.



**Figure S4:** Relationship between uptake of estrone-3-sulfate, measured in 28 human hepatocyte donors and age and gender of the donors. Data were collated from BD Gentest characterization spreadsheets. Uptake was measured at 2  $\mu$ M, over 3 min with 200,000 suspended hepatocytes per incubation. Open symbols are for females, closed symbols for males.

